IPM posted a growth of 8.3%, which is faster as compared to April 2016 (5.5% growth). Major segments like Anti-diabetic and Derma have grown by double digit and Anti Infective segment has not de-grown for the month. FDC related market show a de-growth of -18.4% while the Non FDC market is growing at 8.9% Indian cos showed a de-growth of -7.8% while MNCs showed a de-growth of -39.2% in the FDC segment IPM registered sales worth INR 9474 crs for the month of April 2017

1. Dataset : PharmaTrac MAT APR 2017
PharmaTrac Overview
APR 17

2. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
INDUSTRY DYNAMICS: Market at 8.3 in Apr-17 on the basis of lower growths
in Acute Business…….. Chronic slows down as compared to Mar-17.
7061
7141
7067
7583
7498
8029
7237
7496
7593
7498
7402
7592
8292
7968
8117
8504
8491
8871
8854
8221
8575
8288
8408
8209
8749
8748
8757
9451
9968
10061
9655
9474
9207
9102
8979
8984
9474
17.4
11.6
14.9
12.2
13.2
10.5
22.3
9.7
12.9
10.5
13.6
8.1
5.5
9.8
7.9
11.1
17.4
13.4
9.0
15.2
7.4
9.8
6.8
9.4
8.3
0.0
5.0
10.0
15.0
20.0
25.0
30.0
0
2000
4000
6000
8000
10000
12000
APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
2014-2015 2015-2016 2016-2017 2017-2018 GR % 2015-2016 GR % 2016-2017 GR % 2017-2018
Indian Pharma Market Trends - 2014-

3. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
QOQ DYNAMICS: Q1 - 17 growth at 8.4%......... Growing slower than Q1
2016 and also added lower incremental value as compared to Q1 2016
Q 1 14 Q2 14 Q3 14 Q4 14 Q 1 15 Q 2 15 Q 3 15 Q 4 15 Q 1 16 Q 2 16 Q 3 16 Q 4 16 Q 1 17
INCRE 1199 1961 2757 2136 3170 3109 2757 3324 2413 1876 3613 2685 2159
19322
21268
23109
22326 22492
24378
25867 25650
24906
26254
29480
28335
27065
9474
6.6
10.2
13.5
10.6
16.4
14.6
11.9
14.9
10.7
7.7
14.0
10.5
8.7
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
0
5000
10000
15000
20000
25000
30000
35000
VALUE GR

4. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
8 Corporates in double digit growths for MAT APR-17………..running qrt showing
overall slowdown in growth except for Sun and Zydus who are growing at
double digit . Glaxo on path to recovery
9474
6738
5022
4416
3566 3674 3645
3309
2912 3071
143
133
257
331
549
257
56
66
258 42
11.3
10.5
7.4
12.7
10.4
14.3
11.7
0.5
10.9
12.9
10.1
7.2
2.7
11.2
8.4
4.9
8.9
8.2
6.0
3.8
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
0
2000
4000
6000
8000
10000
12000
SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
AV BV GR RUN-QTR GR APR 17

5. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
ACUTE/CHRONIC SPLIT: Chronic segments still driving grows…..acute
segment slowing the market
GR
IPM SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
11.7 14.9 12.5 14.4 12.5 13.4 15.8 2.1 4.4 24.2 23.6
12.1 14.5 10.5 12.2 9.2 18.2 18.0 15.4 -0.7 1.6 8.9
8.9 6.6 9.5 1.7 15.1 6.3 13.2 11.9 -0.5 11.8 13.3
48
39 39
45 50
56
64
32
66
49
25
32 47
41
42 32
25 11
50
13
30
53
20
14
20
13
18 19
25
18 22 22 22
IPM SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
ACUTE CHRONIC SUB CHRONIC

6. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
RANK SPLIT: Top 10 Contribute 42.9%.......Growth being driven by
medium sized companies
42.90
27.77
13.57
9.97 5.79
APR-16
TOP 10 11 - 25 26 - 50 51 - 100 100 +
42.84
27.74
14.02
9.85 5.55
APR-17
TOP 10 11 - 25 26 - 50 51 - 100 100 +
Apr-16 Apr-17
MAT VAL MS GR CORPORATE MAT VAL MS GR
101257 100.00 12.0 IPM 111859 100.00 10.5
43436 42.90 12.0 TOP 10 47919 42.84 10.3
28116 27.77 13.3 Nov-17 31033 27.74 10.4
13741 13.57 14.9 26 - 50 15678 14.02 14.1
10098 9.97 6.5 51 - 100 11019 9.85 9.1
5867 5.79 9.0 100 + 6210 5.55 5.9

7. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
INDIAN/MNC SPLIT: Indian Companies dominate & are growing above
the Market…
GR VAL : 11.3 GR VAL : 7.3IPM GR VAL : 10.5
0200040006000800010000
SUN*,
9616
CIPLA,
5279
ZYDUS*,
4747
MANKIND
, 4115
ALKEM*,
3931
78.89
21.11
INDIAN MNC
0 2000 4000 6000 8000
ABBOTT*,
6871
GSK, 3375
PFIZER*,
2922
SANOFI
INDIA,
2635
NOVARTIS
, 1082

8. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
* Abbott + Abbott HC + Novo; Alkem + Indchemie + Cachet; Pfizer + Wyeth; Zydus + Biochem; Micro + Bal
ZONAL SPLIT: South dominates…………North zone dragging down the
overall IPM growth……..
26.8%
25.8%
20.1%
23.5%
APR-17
20.1%
23.5%
20.1% 26.7%
22.3% 26.0%
20.0% 27.0%
22.3% 25.6%
SOUTH ZONE
NORTH ZONE
WEST ZONE
EAST ZONE
ZONE
APR-16
MAT VAL APR 17
ZONE MAT VAL MS MS (G / L) GR INCRE VAL
IPM 111859 100.00% 0.00% 10.5 10602
SOUTH ZONE 30165 26.97% 0.22% 11.4 3085
NORTH ZONE 28665 25.63% -0.39% 8.8 2322
WEST ZONE 24903 22.26% -0.08% 10.1 2277
EAST ZONE 22417 20.04% -0.05% 10.2 2073
ALL INDIA ONLY 5709 5.10% 0.30% 17.4 845

9. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
Top 3 Markets constitutes 38% of IPM…….Anti-Diabetics and Cardiac
segment account for almost 29% of the total incremental sales….
MAT VAL APR 17 MS
SUPERGROUP SV BV GR INCRE VAL BV % TO SV SV BV
IPM 111859 4206 10.5 10602 3.8 100.00 100.00
ANTI-INFECTIVES 15942 1248 4.3 655 7.8 14.25 29.66
CARDIAC 13852 119 11.4 1412 0.9 12.38 2.84
GASTRO INTESTINAL 13006 456 10.4 1224 3.5 11.63 10.84
ANTI DIABETIC 9906 74 19.5 1613 0.7 8.86 1.77
VITAMINS / MINERALS / NUTRIENTS 9892 273 9.9 895 2.8 8.84 6.48
RESPIRATORY 8441 347 9.9 761 4.1 7.55 8.25
PAIN / ANALGESICS 7666 340 10.0 694 4.4 6.85 8.09
NEURO / CNS 6807 77 9.5 589 1.1 6.09 1.84
DERMA 6710 205 12.2 731 3.1 6.00 4.87
GYNAECOLOGICAL 5805 491 11.4 593 8.5 5.19 11.67
ANTI-NEOPLASTICS 2396 6 18.1 367 0.3 2.14 0.15
OPHTHAL / OTOLOGICALS 2017 29 6.8 128 1.4 1.80 0.69
VACCINES 2003 102 12.2 218 5.1 1.79 2.43
HORMONES 1861 15 8.2 142 0.8 1.66 0.36
BLOOD RELATED 1392 29 11.8 147 2.1 1.24 0.68
UROLOGY 1300 23 13.0 149 1.8 1.16 0.55
OTHERS 1198 46 17.8 181 3.8 1.07 1.08
SEX STIMULANTS / REJUVENATORS 630 225 14.7 81 35.7 0.56 5.35
ANTI MALARIALS 541 88 -2.0 -11 16.2 0.48 2.09
STOMATOLOGICALS 493 13 7.2 33 2.7 0.44 0.31

10. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
6 out of top 20 brands are Anti-diabetic……………Ultracet has jumped 9
ranks as compared to last MAT and has joined the top 20 club
RANK Apr-17
Apr-17 G/L BRAND SUBGROUP CORPORATE SV AV BV GR INCRE
0 0 IPM 111859 107652 4206 10.5 10602
1 0 MIXTARD HUMAN PREMIX ABBOTT* 514 509 5 3.2 16
2 0 GLYCOMET GP GLIMEPIRIDE + METFORMIN USV 423 415 8 26.6 89
3 0 SPASMO PROXYVON PLUS DICYCLOMINE + PARACETAMOL + TRAMADOL WOCKHARDT 390 389 0.6 21.6 69
4 2 LANTUS GLARGINE SANOFI INDIA 344 342 2 22.8 64
5 2 GALVUS MET VILDAGLIPTIN + METFORMIN NOVARTIS 336 329 7 20.3 57
6 3 LIV 52 HEPATIC PROTECTORS INCLUDING AYURVEDIC HIMALAYA 296 294 2 11.3 30
7 5 JANUMET SITAGLIPTIN + METFORMIN MSD* 292 291 0.8 20.8 50
8 -3 AUGMENTIN AMOXYCILLIN + CLAVULANIC ACID GSK 284 283 1 -9.5 -30
9 1 CLAVAM AMOXYCILLIN + CLAVULANIC ACID ALKEM* 281 242 39 15.2 37
10 -2 MONOCEF CEFTRIAXONE ARISTO 277 213 64 -0.6 -2
11 13 NOVOMIX BIPHASIC ASPART ABBOTT* 269 268 1 48.7 88
12 5 PAN PANTOPRAZOLE ALKEM* 249 243 6 23.4 47
13 2 VOLINI DICLOFENAC SUN* 246 228 18.3 11.5 25
14 5 SYNFLORIX ALL OTHER VACCINES GSK 243 225 17 23.0 45
15 -4 PHENSEDYL COUGH LINCTUS CHLORPHENIRAMINE + CODEINE ABBOTT* 229 229 0 -6.0 -15
16 7 VOVERAN DICLOFENAC NOVARTIS 226 213 13 18.8 36
17 3 FORACORT FORMOTERAL + BUDESONIDE CIPLA 226 223 3 14.5 29
18 -5 BECOSULES VITAMIN B COMPLEX WITH VITAMIN C ONLY PFIZER* 224 217 8 0.2 0
19 -3 ACILOC RANITIDINE CADILA 224 221 3 3.0 6
20 9 ULTRACET PARACETAMOL + TRAMADOL JANSSEN 216 215 1 22.0 39

11. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
6367 Brands launched in last 24 months… 11 out of the top 20
launches are in Chronic categories.
Apr-17
BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL
NI BRANDS(LAST 24 MONTHS) 4376 3356
PANDERM NM CLOBETASOL + NEOMYCIN + MICONAZOLE MACLEODS May-16 100 100
HEPCINAT LP SOFOSBUVIR + LEDIPASVIR NATCO Jan-16 90 53
JARDIANCE EMPAGLIFLOZIN BOEHRINGER INGELHEIM Oct-15 80 66
HEXAXIM COMBINATIONS WITH TETANUS COMPONENT SANOFI INDIA Oct-16 78 78
FORXIGA DAPAGLIFLOZIN ASTRAZENECA May-15 76 36
VIVITRA TRASTUZUMAB ZYDUS* Jan-16 56 52
AXCER TICAGRELOR SUN* Oct-15 48 40
IT-MAC ITRACONAZOLE MACLEODS Oct-15 47 41
ZITAMET PLUS TENELIGLIPTIN + METFORMIN GLENMARK Oct-15 46 33
INSTA MIFEPRISTONE + MISOPROSTOL MACLEODS Apr-16 44 42
SULISENT CANAGLIFLOZIN USV Oct-15 37 29
ONDERO LINAGLIPTIN LUPIN Nov-15 36 29
ZITA PLUS TENELIGLIPTIN GLENMARK Jun-15 34 7
BGR 34 AYURVEDIC AIMIL Oct-15 33 22
TENGLYN TENELIGLIPTIN ZYDUS* Nov-15 30 21
CEREBROLYSIN CEREBROPROTEIN HYDROLYSATE SUN* Jul-15 28 10
ZITEN M TENELIGLIPTIN + METFORMIN GLENMARK Oct-15 27 21
CARIPILL CARICA PAPAYA COMBINATIONS MICRO* Jul-15 26 11
PRIORIX TETRA COMBINATIONS WITH MEASLES AND / OR MUMPS (E.G. MMR) GSK Jul-16 26 26
ONDERO MET LINAGLIPTIN + METFORMIN LUPIN Mar-16 25 24

12. Dataset : PharmaTrac MAT APR 2017 (Val in Crs)(Val in Crs)
70 Brands cross 10 Crs launched………. Overall 99 NIs launched contained plain
Teneligliptin or its combination with Metformin and these brands contributed 10%
to the sales generated by the NIs
Apr-17
BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL
NI BRANDS(LAST 24 MONTHS) 4376 3356
ZITEN TENELIGLIPTIN GLENMARK Jun-15 24 7
AMBRODIL S PLUS LEVOSALBUTAMOL + AMBROXOL ARISTO Aug-16 23 23
NICOTEX PLUS NICOTINE CIPLA Aug-15 22 15
DECA DURABOLIN NANDROLONE ZYDUS* Jan-17 21 21
LUPIHEME ELEMENTAL IRON LUPIN Sep-15 20 15
TENEPRIDE TENELIGLIPTIN MICRO* Nov-15 19 14
GESTAREST MIFEPRISTONE + MISOPROSTOL MACLEODS Mar-16 19 17
DYNAGLIPT TENELIGLIPTIN MANKIND Nov-15 18 14
OCUPOL DX CHLORAMPHENICOL + DEXAMETHASONE + POLYMYXIN B CENTAUR May-15 17 8
TERBINAFORCE LITE CLOTRIMAZOLE + CLOBETASOL + NEOMYCIN MANKIND Jul-16 16 16
TENDIA TENELIGLIPTIN ERIS* Oct-15 16 11
DACIHEP DACLATASVIR ZYDUS* Dec-15 15 12
SINAREST NEW PARACETAMOL + PHENYLEPHRINE + CHLORPHENIRAMINE CENTAUR May-16 15 15
ZEMIGLO GEMIGLIPTIN SANOFI INDIA Apr-16 15 14
DICLOTAL AQ DICLOFENAC BLUE CROSS May-15 14 7
RESOF L SOFOSBUVIR + LEDIPASVIR DR. REDDYS Dec-15 14 13
TENIVA TENELIGLIPTIN INTAS Oct-15 14 9
TENDIA M TENELIGLIPTIN + METFORMIN ERIS* Mar-16 14 13
NOVOGERMINA BACILLUS CLAUSII ALKEM* Apr-16 14 14
GIBTULIO EMPAGLIFLOZIN LUPIN Sep-16 14 14

13. Dataset : PharmaTrac MAT APR 2017